Wound Healing Peptides: GHK-Cu, LL-37, KLOW and GLOW

Wound healing peptides are primarily discussed in preclinical research. Alongside BPC-157 and TB-500, GHK-Cu and LL-37 appear regularly. Both are biologically better characterised than proprietary blends such as KLOW and GLOW.

This article summarises the substantiated core findings from wound healing research and separates them from points that are currently only partially assessable.

GHK-Cu: The Copper Peptide in Tissue Repair

Structure and Discovery

GHK-Cu (Glycyl-L-Histidyl-L-Lysine-Copper) is a naturally occurring tripeptide bound to a copper(II) ion. It was described in human plasma in the 1970s by Loren Pickart. A later overview of GHK and its biological functions can be found in Pickart and Margolina (PMID 18644225).

The concentration of GHK in plasma decreases with age. This relationship is revisited in a more recent review on the role of GHK in ageing research (PMID 35083444).

Mechanisms of Action in Wound Healing

Reviews and preclinical studies discuss the following mechanisms for GHK-Cu:

• Extracellular matrix: GHK-Cu is associated with collagen formation, matrix remodelling and tissue repair.
• Fibroblasts and keratinocytes: Effects on cells relevant to repair and re-epithelialisation were observed in cell and tissue models.
• Inflammation-related processes: Modulatory effects on oxidative and inflammatory signals are described.
• Tissue remodelling: The literature assigns GHK-Cu a regulatory influence on remodelling processes rather than a single, clearly defined MMP axis.

Skin Regeneration and Scar Research

In skin research particularly, GHK-Cu has been investigated for years as a candidate for tissue repair and matrix remodelling. A review by Pickart and Margolina describes effects on wound healing, tissue remodelling and skin repair (PMID 29986520). The earlier overview (PMID 18644225) also supports the general classification of GHK as a signalling peptide in the context of repair processes.

Less substantiated, by contrast, are very specific claims about individual MMP subtypes or precisely quantified, concentration-dependent effects. Such details are often sharpened in secondary literature but are not always supported by a clear primary source.

Caution is also warranted regarding hair follicles. There are older indications that copper-containing peptides may be relevant in dermatological models. However, the available literature is not consistent enough to justify a strong claim for GHK-Cu alone in this area.

GHK-Culongevity

Naturally occurring copper tripeptide complex for skin regeneration and anti-aging research. Stimulates collagen synthesis, accelerates wound healing, and modulates 4000+ genes. Plasma levels decline with age, making it a key target in longevity research.

LL-37: The Human Cathelicidin

Structure and Biological Role

LL-37 is the only human cathelicidin. The peptide consists of 37 amino acids and is cleaved from the precursor protein hCAP-18. It is produced by neutrophils, macrophages, epithelial cells and keratinocytes, among others.

LL-37 is part of innate immunity and combines antimicrobial activity with functions relevant to tissue repair. An overview of this dual function can be found in reviews on the antimicrobial and immunomodulatory role of LL-37 (PMID 22460279).

Antimicrobial Activity

The literature describes a broad antimicrobial profile for LL-37:

• Bacteria: Activity against various gram-positive and gram-negative bacteria has been demonstrated in experimental models.
• Fungi: Antifungal effects have also been described.
• Viruses: Antiviral properties have additionally been investigated in various models.

An important aspect for wound healing research is the biofilm topic. LL-37 can influence biofilm formation and disrupt established bacterial biofilms in certain models. However, the magnitude of this effect depends significantly on the pathogen, concentration, medium and test system. Firm statements with fixed log reductions or very short timeframes should therefore only be made with an exactly cited primary source.

Immunomodulation and Wound Healing

Three areas are particularly relevant for wound healing-related research:

• Keratinocyte migration: LL-37 can promote keratinocyte migration via the EGFR signalling pathway (PMID 16177113).
• Angiogenesis: Pro-angiogenic effects have been described in multiple studies (PMID 12782669, PMID 23766266).
• Immunomodulation: LL-37 influences cytokines, chemokines and cell recruitment, and is therefore regarded not only as an antimicrobial but also as a regulatory peptide (PMID 22460279).

Relevance in Chronic Wounds

The combination of antimicrobial activity, influence on keratinocytes and relationship to angiogenesis makes LL-37 a plausible research subject for chronic or infection-burdened wounds. This does not mean, however, that its role in complex wound models has already been conclusively established.

Caution is also warranted with new carrier systems for LL-37, such as in wound dressings or fibre structures: such approaches are logically sound from a research perspective, but are strongly dependent on the particular material system and preclinical model.

KLOW and GLOW: Proprietary Healing Blends

The Blend Approach in Peptide Research

The idea behind peptide blends is understandable: multiple components are intended to cover different phases of a repair process simultaneously. However, such an approach can only be scientifically evaluated properly when the exact composition, dosage and experimental testing of the specific blend are disclosed.

KLOW - Advanced Tissue Repair (80 mg)

KLOW is offered as a proprietary blend at 80 mg. Without a disclosed composition, it is not possible to state reliably which molecular signalling pathways the product addresses individually, or how well product-specific claims about wound healing are scientifically supported.

For research purposes this means: KLOW can be described as a product category, but not with the same certainty as a single, well-characterised peptide like GHK-Cu or LL-37.

KLOWregeneration

4-in-1 anti-aging peptide blend: GHK-Cu 50mg + BPC-157 10mg + TB-500 10mg + KPV 10mg. Targets collagen synthesis, tissue regeneration, skin repair, and anti-inflammatory pathways.

GLOW - Tissue Regeneration (70 mg)

GLOW is likewise a proprietary blend at 70 mg. The same applies here: without a published ingredient list and without product-specific data, mechanistic statements are only partially possible.

A sober formulation is therefore appropriate: GLOW is positioned for research questions on tissue regeneration, but its scientific assessability depends on whether the contained components and the associated data are made transparent.

GLOWregeneration

3-in-1 skin peptide blend: GHK-Cu 50mg + BPC-157 10mg + TB-500 10mg. Targets collagen synthesis, tissue regeneration, and skin repair for comprehensive dermatological research.

Comparison: Which Peptide for Which Research Purpose?

The choice of the appropriate peptide depends on the specific model. From the current perspective, the classification can be cautiously summarised as follows:

Antimicrobial

LL-37 is most relevant when antimicrobial activity, biofilm questions and immunomodulation are to be investigated.

Structural

GHK-Cu is more closely linked in the literature to matrix remodelling, skin repair and wound healing-related repair processes.

Exploratory

KLOW and GLOW can be of interest for exploratory research designs. Without transparent formulation and reliable product-specific data, however, they remain considerably more difficult to classify scientifically than individual defined peptides.

Combination Options in Research

Combining different healing peptides is a plausible research approach. The current evidence is, however, mostly preclinical, heterogeneous and model-dependent.

GHK-Cu + BPC-157

The combination of GHK-Cu with BPC-157 is primarily of theoretical interest, as matrix remodelling and generally regeneration-related signalling pathways could complement each other. However, broad, well-standardised documentation specifically for this combination is not available.

LL-37 + TB-500

The combination of LL-37 with TB-500 should also be understood more as a hypothesis for combined antimicrobial and migration-related research than as a well-documented standard approach.

Frequently Asked Questions

This article serves exclusively for scientific information and research purposes. The peptides described are not intended for human consumption and are not approved as medicinal products. All statements refer to published preclinical studies, reviews and in vitro research.